Title Image

R&D

HND-002
Indication ­ ‒ ­Healing of all grades of erosive esophagitis (EE)
­ ‒ ­Maintaining healing of EE
­­‒ Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD)
Status First- to File (FTF), the commercialization partner, Par, received final approval in April 2017.
Product Advantages ­ ‒ FTF, 180-day market exclusivity right in the USA.
­ ‒ settled with the brand company.
Potential Market The market value of branded drug is about $1 billion per year. Par, a commercialization partner of Handa, is expected to occupy a certain market share.

judi online infini88 slot pg slot baccarat online slot idn live idn poker judi bola tangkasnet pragmatic slot88 sbobet slot deposit dana casino online vegas slot pokerseri joker123 autowin88 warungtoto selot